Nabriva Therapeutics plc announced that Elyse Seltzer, M.D., has decided to resign from her position as chief medical officer effective as of September 30, 2017 to pursue other professional endeavors. In the interim, Dr. Colin Broom, chief executive officer, will also assume the role of chief medical officer. Dr. Seltzer has agreed to continue to serve as a consultant to the company through the end of the first quarter of 2018 and will provide input as required as the company prepares to un-blind and analyze data from the company's first pivotal Phase 3 clinical trial of lefamulin, LEAP 1.